Wissenschaftliche Veröffentlichungen von Mitarbeitern der Diabetes-Klinik
2009
Hamann A: Insulintherapie in der Intensivmedizin. Klinikarzt 38: 502-506, 2009
Schlotterer A, Kukudov G, Bozorgmehr F, Hutter H, Du X, Oikonomou D, Ibrahim Y, Pfisterer F, Rabbani N, Thornalley P, Sayed A, Fleming T, Humpert P, Schwenger V, Zeier M, Hamann A, Stern D, Brownlee M, Bierhaus A, Nawroth P, Morcos M: C. elegans as model fort he study of high glucose mediated lifespan reduction. Diabetes 58:2450-2456, 2009
Hamann A: Aktuelles zur Adipositas. Diabetologe 5: 420-431, 2009
Humpert PM, Morcos M, Oikonomou D, Schaefer K, Hamann A, Bierhaus A, Nawroth PP: External electric muscle stimulation improves burning sensations and sleeping disturbances in patients with type 2 diabetes and symptomatic neuropathy. Pain Medicine 10: 413-419, 2009
Hamann A: Antidiabetische Therapie und Gewichtskontrolle. Adipositas 3: 77-81, 2009
Rudofsky G, Schlotterer A, Reismann P, Grafe IA, Tafel J, Morcos M, Humpert PM, Bierhaus A, Hamann A: The -174G/C IL-6 gene promoter polymorphism and diabetic microvascular complications. Horm Metab Res 41: 308-313, 2009
Pfeiffer A, Hamann A: Genetik des Typ-1- und Typ-2-Diabetes und dominant erblicher Diabetesformen. In: Kursbuch Diabetologie, 2. Auflage (Nauck M, Hensen J, Brabant G, Hauner H, ed.), Kirchheim-Verlag, Mainz (im Druck)
2008
Morcos M, Schlotterer A, Sayed AA, Kukudov G, Oikomonou D, Ibrahim Y, Pfisterer F, Schneider J, Bozorgmehr F, Rudofsky Jr G, Schwenger V, Kientsch-Engels R, Hamann A, Zeier M, Dugi K, Yard B, Humpert PM, Woude FV, Nawroth PP, Bierhaus A: Rosiglitazone Reduces Angiotensin II and Advanced Glycation End Produkt-dependent Sustained Nuclear Factor-kappaB Activation in Cultured Human Proximal Tubular Epithelial Cells. Horm Metab Res 40:752-759, 2008
Rosenstock J, Chou H, Mattaei S, Seidel DK, Hamann A: Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes. Diabetes Obes Metab 10: 862-873, 2008
Hamann A: Klinische Aspekte der Adipositas. In: Handbuch Essstörungen und Adipositas (Herpertz S, de Zwaan M, Zipfel S, Hrsg.), Springer Verlag, Heidelberg, 271-279, 2008
von Eynatten M, Humpert PM, Bluemm A, Lepper PM, Hamann A, Allolio B, Nawroth PP, Bierhaus A, Dugi KA: High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis 199: 123-128, 2008
Hamann A, Tafel J: Nutzen und Risiko der medikamentösen Adipositastherapie. Diabetologe 4: 266-271, 2008.
Von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D: Atherogenic dyslipidemia but not total and high molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J 29: 1307-1315, 2008
Morcos M, Du X, Pfisterer F, Hutter H, Sayed AA, Thornalley P, Ahmed N, Baynes J, Thorpe S, Kukudov G, Schlotterer A, Bozorgmehr F, El Baki RA, Stern D, Moehrlen F, Hamann A, Becker C, Zeier M, Schwenger V, Miftari N, Humpert P, Hammes HP, Buechler M, Bierhaus A, Brownlee M, Nawroth PP: Glyoxalase-1 prevents mitochrondial protein modification and enhances lifespan in C. elegans. Aging Cell 7, 260-269, 2008
Blüher M, Hamann A: Adipositas und metabolisches Syndrom. Diabetologie 3: R1-R18, 2008
Hamann A: Adipositas - eine Volkskrankheit (?). Gynäkologische Endokrinologie 6: 14-19, 2008
Hamann A, Garcia-Puig J. Paul G, Donaldson J, Stewart M: Comparison of fixed-dose rosiglitazone/metform combination therapy with sulfonylurea plus metformin in overweight individuals with type 2 diabetes poorly controlled on metformin alone. Exp Clin Endocrinol Diabetes 116: 6-13, 2008
Hamann A: Pharmakotherapie der Adipositas. Internist 49: 106-113, 2008
Rudofsky G, Schlotterer A, Humpert PM, Tafel J, Morcos M, Nawroth PP, Bierhaus A, Hamann A: A M55V polymorphism in the SUMO4 gene is associated with a reduced prevalence of diabetic retinopathy in patients with type 1 diabetes. Exp Clin Endocrinol Diabetes 116: 14-17, 2008
2007
Rudofsky G, Reismann P, Grafe IA, Konrade I, Djuric Z, Tafel J, Buchbinder S, Zorn M, Humpert PM, Hamann A, Morcos M, Nawroth PP, Bierhaus A: Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-ĸB binding activity. Horm Metab Res 39: 665-671, 2007
Rudofsky G, Schlotterer A, Nawroth PP, Bierhaus A, Hamann A: SUMO4 M55V variant is not associated with diabetic nephropathy in Caucasians. Diabetes 58: e11, 2007 (Letter)
Hamann A: Die Bedeutung des metabolischen Syndroms im klinischen Alltag. Klinikarzt 36: 383-388, 2007
Humpert PM, Kopf S, Djuric Z, Laine K, Korosoglou G, Rudofsky G, Hamann A, Morcos M, von Eynatten M, Nawroth PP, Bierhaus A: Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients. Diabetologia 50: 1517-1522, 2007
Morcos M, Fohr B, Tafel J, Pfisterer F. Hamann A, Humpert P, Bode H, Schwenger V, Zeier M, Becker C, Kasperk C, Schilling T, Hammes HP, Bierhaus A, Nawroth PP: Long-Term Treatment of Central Cushing's Syndrome with Rosiglitazone, Exp. Clin Endocrinol Diabetes 115: 292-297, 2007
von Eynatten M, Hamann A: Adipokine und Lipidstoffwechsel bei Typ-2-Diabetes, Dtsch Med Wochenschr 132: 1048-1052, 2007
Hamann A, Hammes HP, Nawroth P: Diabetes im Spannungsfeld zwischen Wissenschaft, Leitlinien und IQWIG, Dtsch Med Wochenschr 132: 1062-1064, 2007
Rudofsky G, Schrödter A, Voron'ko OE, Schlotterer A, Humpert PM, Tafel J, Nawroth PP, Bierhaus A, Hamann A: Promoter polymorphisms of UCP1, UCP2 and UCP3 are not associated with diabetic microvascular complications in type 2 diabetes. Horm Metab Res 39: 306-309, 2007
Tafel J, Nawroth PP, Hamann A: Präventionsmaßnahmen: Ernährung und "Lifestyle", in: Handbuch der Fettstoffwechselstörungen, 3. Aufl. (Schwandt P, Parhofer KG, ed.), Schattauer Verlag, Stuttgart, New York, 1016-1034, 2007
Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M: Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes 31: 138-146, 2007
2006
Hamann A: Entwicklung des Körpergewichts unter antidiabetischer Therapie. Dtsch Med Wochenschr 131 (Suppl 8): S255-S228, 2006
Hamm CW, Hamann A: Differenzielle Therapie bei Diabetikern mit akutem Koronarsyndrom. Dtsch Med Wochenschr 131 (Suppl 7): S208-S210, 2006
Stewart MW, Cirkel DT, Furuseth K, Donaldson J, Biswas N, Starkie MG, Phenekos C, Hamann A: Effect of metformin plus rosiglitazone compared with metformin alone on glycemic control in well-controlled type 2 diabetes. Diabet Med 23: 1069-1078, 2006
Hamann A, Morcos M, Nawroth P: Diabetes mellitus Typ 2 - Medikamentöse Therapie. CME 3: 11-20, 2006
Hansen-Algenstaedt N, Algenstaedt P, Schaefer C, Hamann A, Wolfgang L, Cingoz G, Kilic N, Schwarzloh B, Schroeder M, Joschek C, Wiesner L, Ruther W, Ergun S: Neural driven angiogenesis by overexpression of nerve growth factor. Histochem Cell Biol 125: 637-649, 2006
Hamann A, Lichtenstein S: Ursachen der Adipositas - Genetik contra Verhältnisse contra Verhalten. In: Übergewicht bei Kindern und Erwachsenen - ein unendliches Thema?, Deutsche Gesellschaft für Ernährung, 17-21, 2006
von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D: Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia and heart failure in patients with coronary heart disease. Clin Chem 52: 853-859, 2006
Eisenhardt S, Schwarzmann N, Henschel V, Germeyer A, von Wolff M, Hamann A, Strowitzki T: Early Effects of Metformin on Women with Polycystic Ovary Syndrome (PCOS): A Prospective Randomized Double-Blind Placebo-Controlled Trial. J Clin Endocrinol Metab 91: 946-952, 2006.
Hamann, A: Pharmakotherapie der Adipositas, MMW Fortschr Med. 148 (Heft 9): 36-38, 2006
Pfützner A, Schöndorf S, Seidel D, Winkler K, Matthaei S, Hamann A, Forst T: Impact of rosiglitazone on beta-cell function, insulin resistance and adiponectin concentrations results from a double-blind oral combination study with glimepiride. Metabolism 55: 20-25, 2006
Hamann A: Adipositas und Depression. In: Depression und komorbide Störungen, (Müller WE, Volz HP, ed.), LinguaMed Verlag, Neu-Isenburg, 61-74, 2006
Rudofsky G, Schrödter A, Schlotterer A, Voronko OE, Schlimme M, Tafel J, Isermann B, Humbert PM, Morcos M, Bierhaus A, Nawroth PP, Hamann A: Functional polymorphisms of UCP2 and UCP3 are associated with a reduced prevalence of diabetic neuropathy in patients with type 1 diabetes. Diabetes Care 29: 89-94, 2006
2005
Hamann, A: Adipositastherapie: Was bringen Medikamente?
Allgemeinarzt 27 (15): 30-32, 2005
Pfeiffer A, Hamann A: Genetik des Typ-1- und Typ-2-Diabetes und dominant erblicher Diabetesformen.
In: Kursbuch Diabetologie (Nauck M, Brabant G, Hauner H, ed.), Kirchheim-Verlag, Mainz, 24-30, 2005
Toplak H, Ziegler N, Keller F, Hamann A, Godin C, Wittert G, Zanella MT, Zuniga-Guajardo S, van Gaal L: X-PERT: Orlistat reduces weight in obese subjects receivig a mildly reduced-caloric diet or moderate diet. Early response to treatment predicts weight maintenance. Diabetes Obes Metab 7: 699-708, 2005
Hamann A, Bellou V, Strowitzki T, Morcos M: Polycystisches Ovarsyndrom in der allgemeinmedizinischen Praxis. Tägl. Praxis 46: 291-302, 2005
Hamann, A: Adipositas. In: Innere Medizin, 12. Auflage (Greten, H. ed.), Georg Thieme Verlag, Stuttgart, New York, 633-636, 2005
Humpert PM, Neuwirt R, Battista MJ, Voronko O, von Eynatten M, Konrade I, Rudofsky G, Wendt T, Hamann A, Morcos M, Nawroth PP, Bierhaus A: SDF1-3A/G genotype enhances recruitment of CD34/133-positive progenitor cells in poorly controlled type 2 diabetes mellitus. Diabetes Care 28: 934-936, 2005
Rudofsky G, Schlimme M, Schlotterer A, von Eynatten M, Reismann P, Tafel J, Grafe I, Morcos M, Nawroth PP, Bierhaus A, Hamann A: No association of the 94 T/G polymorphism in the adiponectin gene with diabetic complications. Diabetes Obes Metab 7: 455-459, 2005
von Eynatten M, Schneider JG, Hadziselimovic S, Hamann A, Bierhaus A, Nawroth PP, Dugi KA: Adipocytokines as a novel target for the inflammatory action of atorvastatin in patients with type 2 diabetes. Diabetes Care 28: 754-755, 2005
Chen J, Kasper M, Nakagawa K, Bai L, Wu G, Zhang Y, Humpert PM, Andrassy M, Luther T, Schiekofer S, Chen B, Morcos M, Hamann A, Stern DM, Nawroth PP, Bierhaus A: Tissue factor as a link between wounding and tissue repair.Diabetes 54: 2143-2154, 2005
2004
Rudofsky jr. G, Reismann P, Humpert PM, Isermann B, Chavakis T, Tafel J, Nosikov V, Hamann A, Nawroth PP, Bierhaus A: Asp299Gly and Thr399Ile genotypes of the TLR4 gene are associated with a reduced prevalence of diabetic neuropathy in patients with type 2 diabetes. Diabetes Care 27: 179-183, 2004.
Rudofsky G Jr, Chen J, Isermann B, Schilling T, Schiekofer S, Andrassy M, Schneider JG, Morcos M, Hamann A, Humpert PM, Sayed AAR, Witte S, Renn W, Pfohl M, Nosikov V, Schleicher E, Häring HU, Rudofsky G Sr, Ritz E, Nawroth PP, Bierhaus A: A 63bp deletion in the promoter of RAGE protects patients with diabetes type 2 from nephropathy. Exp Clin Endocrinol Diabetes 112: 135-141, 2004.
Durrington PN, Tuomilehto J, Hamann A, Smith K, Kallend D: Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidemia. Diabetes Res Cln Pract 64: 137-151, 2004.
Hildebrandt W, Hamann A, Krakowski-Rosen H, Kinscherf R, Dugi K, Sauer R, Lacher S, Nöbel N, Bodens A, Bellou V, Edler L, Nawroth PP, Dröge W: Effect of thiol antioxidant on body fat and insulin reactivity. J Mol Med 82: 336-344, 2004.
Reismann P, Lichy C, Rudofsky G, Humpert PM, Genius J, Si TD, Dörfer C, Grau AJ, Hamann A, Hacke W, Nawroth PP, Bierhaus A: Lack of association between polymorphisms of the toll-like receptor 4 gene and cerebral ischemia. J Neurol 251: 853-858, 2004
Schneider JG, von Eynatten M, Parhofer KG, Volkmaer JE, Schiekofer S, Hamann A, Nawroth PP, Dugi KA:Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis 175: 325-331, 2004
Oberdorfer K, Swoboda S, Hamann A, Bärtsch U, Kusterer K, Born B, Hoppe-Tichy T, Geiss HK, von Baum H: Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J Antimicrob Chemother 54: 836-839, 2004.
Tafel J, Branscheid I, Skwarna B, Schlimme M, Algenstaedt P, Hinney A, Hebebrand J, Nawroth PP, Hamann A: Variants in the human ß1-, ß2- and ß3-adrenergic receptor genes are not associated with morbid obesity in children and adolescents. Diabetes Obes Metab 6: 452-455, 2004.
Rudofsky G, Reismann P, Schiekofer S, Petrov D, von Eynatten M, Humpert PM, Isermann B, Müller-Hoff C, Thai TP, Lichtenstein S, Bärtsch U, Hamann A, Nawroth PP, Bierhaus A: Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappa B activation in PBMCs. Horm Metab Res 36: 630-638, 2004.
von Eynatten M, Schneider JG, Humpert PM, Rudofsky G, Schmidt N, Barosch P, Hamann A, Morcos M, Kreuzer J, Bierhaus A, Nawroth PP, Dugi KA: Decreased plasma lipoprotein lipase in hypoadiponectinemia: An association independent of systemic inflammation and insulin resistance. Diabetes Care 27: 2925-2929, 2004.
Nawroth PP, Schilling T, Hamann A, Morcos M, Kasperk C: Schilddrüsenhormone und Funktion des vaskulären Endothels. Z Ärztl Fortbild Qualitätssich 98 (Suppl 5): 33-35, 2004.
Hamann A, Bellou V, Strowitzki, Morcos M: Polycystisches Ovarsyndrom in der internistischen Praxis. Internist Prax 44: 47-58, 2004.
Hamann A, Morcos M: Auswirkung einer Gewichtsabnahme auf Prävention und Therapie des Typ-2-Diabetes. CardioVasc 4: 36-40, 2004.
Nawroth PP, Hamann A, Mattern R: Verhalten der Ärzte angesichts von Mordversuchen mit Insulin bei schwerst pflegebedürftigen alten Menschen. Diab Stoffw 13: 205-208, 2004.
Isermann B, Bierhaus A, Humpert PM, Rudofsky G, Chavakis T, Ritzel R, Wendt T, Morcos M, Kasperk C, Hamann A, Nawroth PP: AGE-RAGE: eine Hypothese oder ein Mechanismus ? Herz 29:504-509, 2004.
Hamann A, Morcos M, Nawroth PP: Orale Diabeteseinstellung: was ist wann indiziert ? Internist 45: 1556-1563, 2004
Hamann A, Morcos M: Subklinische Hypothyreose und kardiovaskuläres Risiko In: Schilddrüse 2003 (Dietlein M, Schicha H, ed.), Walter de Gruyter Verlag, Berlin, New York, 273-280, 2004
Bierhaus A, Humpert PM, Rudofsky G, Chavakis T, Wendt T, Hamann A, Nawroth PP: Inflammation. In: Diabetes und Herz (Meinertz T, Rösen P, Schömig A, Tschöpe D, Ziegler D, ed.), Dr. Dietrich Steinkopff Verlag, Darmstadt, 55-64, 2004
|
